Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections.

Sauermann R, Burian B, Burian A, Jäger W, Höferl M, Stella A, Theurer S, Riedl M, Zeitlinger M.

J Antimicrob Chemother. 2013 Apr;68(4):895-9. doi: 10.1093/jac/dks479. Epub 2012 Dec 4.

2.

Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis.

Burkhardt O, Brunner M, Schmidt S, Grant M, Tang Y, Derendorf H.

J Antimicrob Chemother. 2006 Sep;58(3):632-6. Epub 2006 Jul 12.

3.

Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections.

Traunmüller F, Schintler MV, Spendel S, Popovic M, Mauric O, Scharnagl E, Joukhadar C.

Int J Antimicrob Agents. 2010 Jul;36(1):84-6. doi: 10.1016/j.ijantimicag.2010.03.007. Epub 2010 Apr 24.

PMID:
20456925
4.

Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.

Traunmüller F, Schintler MV, Metzler J, Spendel S, Mauric O, Popovic M, Konz KH, Scharnagl E, Joukhadar C.

J Antimicrob Chemother. 2010 Jun;65(6):1252-7. doi: 10.1093/jac/dkq109. Epub 2010 Apr 7.

5.

Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections.

Majcher-Peszynska J, Haase G, Sass M, Mundkowski R, Pietsch A, Klammt S, Schareck W, Drewelow B.

Eur J Clin Pharmacol. 2008 Nov;64(11):1093-100. doi: 10.1007/s00228-008-0531-5. Epub 2008 Jul 25.

PMID:
18654767
6.

Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.

Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J.

Int J Antimicrob Agents. 2009 May;33(5):432-6. doi: 10.1016/j.ijantimicag.2008.10.005. Epub 2008 Dec 16.

PMID:
19091521
7.
8.

Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers.

Wiskirchen DE, Housman ST, Quintiliani R, Nicolau DP, Kuti JL.

Pharmacotherapy. 2013 Mar;33(3):266-74. doi: 10.1002/phar.1197. Epub 2013 Feb 11.

PMID:
23400916
9.

Pharmacokinetics of free ertapenem in critically ill septic patients: intermittent versus continuous infusion.

Breilh D, Fleureau C, Gordien JB, Joanes-Boyau O, Texier-Maugein J, Rapaport S, Boselli E, Janvier G, Saux MC.

Minerva Anestesiol. 2011 Nov;77(11):1058-62. Epub 2011 May 11.

10.

Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections.

Zhou J, Sulaiman Z, Llorin RM, Hee KH, Lee LS, Lye DC, Fisher DA, Tam VH.

J Antimicrob Chemother. 2014 Sep;69(9):2517-21. doi: 10.1093/jac/dku143. Epub 2014 May 5.

11.

High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.

Schintler MV, Traunmüller F, Metzler J, Kreuzwirt G, Spendel S, Mauric O, Popovic M, Scharnagl E, Joukhadar C.

J Antimicrob Chemother. 2009 Sep;64(3):574-8. doi: 10.1093/jac/dkp230. Epub 2009 Jul 3.

12.

Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients.

Frasca D, Marchand S, Petitpas F, Dahyot-Fizelier C, Couet W, Mimoz O.

Antimicrob Agents Chemother. 2010 Feb;54(2):924-6. doi: 10.1128/AAC.00836-09. Epub 2009 Nov 23.

13.

Diffusion of ertapenem into bone and synovial tissues.

Boselli E, Breilh D, Djabarouti S, Bel JC, Saux MC, Allaouchiche B.

J Antimicrob Chemother. 2007 Oct;60(4):893-6. Epub 2007 Aug 17.

14.

Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents.

Abdel-Rahman SM, Kearns GL, Topelberg S, Jacobs RF, Mistry GC, Majumdar A, Xu Y, Wagner JA, Kitchen CJ, Groff M, Herman G, Blumer JL.

Pediatr Infect Dis J. 2010 Dec;29(12):1072-6. doi: 10.1097/INF.0b013e3181e82608.

15.

Ertapenem peritoneal fluid concentrations in adult surgical patients.

Arrigucci S, Garcea A, Fallani S, Cassetta MI, Canonico G, Tonelli F, Mazzei T, Novelli A.

Int J Antimicrob Agents. 2009 Apr;33(4):371-3. doi: 10.1016/j.ijantimicag.2008.09.015. Epub 2008 Dec 20.

PMID:
19097758
16.

Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.

Tice AD, Turpin RS, Hoey CT, Lipsky BA, Wu J, Abramson MA.

Am J Health Syst Pharm. 2007 May 15;64(10):1080-6.

PMID:
17494908
17.

Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis.

Cardone KE, Grabe DW, Kulawy RW, Daoui R, Roglieri J, Meola S, Drusano GL, Lodise TP.

Antimicrob Agents Chemother. 2012 Feb;56(2):725-30. doi: 10.1128/AAC.05515-11. Epub 2011 Nov 14.

18.

Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.

Zhanel GG, Derkatch S, Laing N, Noreddin AM, Hoban DJ.

J Antimicrob Chemother. 2007 Jan;59(1):144-7. Epub 2006 Nov 1.

19.

Pharmacokinetics of ertapenem in colorectal tissue.

Wittau M, Scheele J, Bulitta JB, Mayer B, Kaever V, Burhenne H, Henne-Bruns D, Isenmann R, Brockschmidt C.

Chemotherapy. 2011;57(5):437-48. doi: 10.1159/000333377. Epub 2011 Dec 22.

PMID:
22189340
20.

Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS Jr.

Antimicrob Agents Chemother. 2006 Apr;50(4):1222-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk